Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (AMARONE)

9 oktober 2026 bijgewerkt door: EyeBiotech Ltd.

A 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Single-masked Comparative Safety and Preliminary Efficacy Study of Intravitreal (IVT) Remigromig in a Mixed Population of Participants With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

Studie Overzicht

Gedetailleerde beschrijving

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

33

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Caba, Argentinië, 1023
        • Caba, Argentina
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentinië, C1121ABB
        • Ciudad Autonoma Buenos Aires
    • PR
      • Arecibo, PR, Puerto Rico, 00612
        • Arecibo, PR
      • London, Verenigd Koninkrijk, W1G7LB
        • London, UK
    • England
      • London, England, Verenigd Koninkrijk, NW10 7NS
        • London, England
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85032
        • Phoenix, AZ
    • California
      • Bakersfield, California, Verenigde Staten, 93309
        • Bakersfield, CA
      • Modesto, California, Verenigde Staten, 95356
        • Modesto, CA
      • Mountain View, California, Verenigde Staten, 94040
        • Mountain View, CA
      • Sacramento, California, Verenigde Staten, 95825
        • Sacramento, CA
      • Sacramento, California, Verenigde Staten, 95841
        • Sacramento, CA
    • Colorado
      • Colorado Springs, Colorado, Verenigde Staten, 80909
        • Colorado Springs, Colorado
      • Lakewood, Colorado, Verenigde Staten, 80288
        • Lakewood, CO
    • Florida
      • Pompano Beach, Florida, Verenigde Staten, 33064
        • Pompano Beach
    • Illinois
      • Lemont, Illinois, Verenigde Staten, 60439
        • Lemont, NV
    • Maryland
      • Hagerstown, Maryland, Verenigde Staten, 21740
        • Hagerstown, MD
    • Nevada
      • Reno, Nevada, Verenigde Staten, 89502
        • Reno, NV
    • South Carolina
      • West Columbia, South Carolina, Verenigde Staten, 29169
        • West Columbia, SC
    • Tennessee
      • Germantown, Tennessee, Verenigde Staten, 38138
        • Germantown, TN
      • Knoxville, Tennessee, Verenigde Staten, 37922
        • Knoxville, TN
      • Nashville, Tennessee, Verenigde Staten, 37203
        • Nashville, TN
    • Texas
      • Abilene, Texas, Verenigde Staten, 79606
        • Abilene, TX
      • Amarillo, Texas, Verenigde Staten, 79109
        • Amarillo, TX
      • Austin, Texas, Verenigde Staten, 78705
        • Austin, TX
      • Bellaire, Texas, Verenigde Staten, 77401
        • Bellaire, TX
      • Dallas, Texas, Verenigde Staten, 75231
        • Dallas, TX
      • Katy, Texas, Verenigde Staten, 77494
        • Katy, TX
      • McAllen, Texas, Verenigde Staten, 78503
        • McAllen, TX
      • Plano, Texas, Verenigde Staten, 75075
        • Plano, TX
      • Round Rock, Texas, Verenigde Staten, 78681
        • Round Rock, TX
      • San Antonio, Texas, Verenigde Staten, 78240
        • San Antonio, TX
      • The Woodlands, Texas, Verenigde Staten, 77384
        • The Woodlands, TX

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

50 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
  • DME patients must be ≥ 18 years of age, NVAMD patients must be ≥ 50 years of age
  • Diagnosis of either DME or NVAMD. DME patients must be treatment naïve. NVAMD patients can be either treatment naïve or treatment experienced.
  • DME patients must have vision loss in the study eye
  • NVAMD patients can be either treatment-naïve or treatment experienced with vision loss in the study eye

Exclusion Criteria:

  • Be pregnant or breastfeeding
  • History of cataract surgery and/or minimally invasive glaucoma surgery (MIGS) within 3 months of Screening
  • Yttrium-Aluminum Garnet (YAG) laser capsulotomy within 2 months of Screening
  • Any other condition except for DME or NVAMD or that could affect interpretation of study assessments

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Dose 1

Part 1 MAD Portion Dose 1 - Low Dose

Remigromig is a humanized antibody formulated for IVT administration

Andere namen:
  • EYE103
Experimenteel: Dose 2

Part 1 MAD Portion Dose 2 - Low-Mid Dose

Remigromig is a humanized antibody formulated for IVT administration

Andere namen:
  • EYE103
Experimenteel: Dose 3

Part 1 MAD Portion Dose 3 - Mid-High Dose

Remigromig is a humanized antibody formulated for IVT administration

Andere namen:
  • EYE103
Experimenteel: Dose 4

Part 1 MAD Portion Dose 4 - High Dose

Remigromig is a humanized antibody formulated for IVT administration

Andere namen:
  • EYE103
Experimenteel: DME Medium Dose

Part 2 Naïve DME monotherapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

Andere namen:
  • EYE103
Experimenteel: DME High Dose

Part 2 Naïve DME monotherapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

Andere namen:
  • EYE103
Experimenteel: Naïve NVAMD Medium Dose

Part 2 Naïve NVAMD combination therapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

Andere namen:
  • EYE103
Experimenteel: Naïve NVAMD High Dose

Part 2 Naïve NVAMD combination therapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

Andere namen:
  • EYE103
Experimenteel: Experienced NVAMD Medium Dose

Part 2 Experienced NVAMD combination therapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

Andere namen:
  • EYE103
Experimenteel: Experienced NVAMD High Dose

Part 2 Experienced NVAMD combination therapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

Andere namen:
  • EYE103

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
Tijdsspanne: Up to approximately 12 weeks

Systemic DLTs are defined as a Grade III (severe), IV (life threatening) or V (death related to adverse event) toxicities as defined in the National Cancer Institute (NCI) Common Toxicity Criteria, or any significant severe toxicity deemed related to study drug by the principal investigator. Ocular DLTs are defined as: loss of 4 or more lines of visual acuity, clinically significant inflammation, increase of intra-ocular pressure (IOP) from baseline of > or =15 mmHg, accelerated formation of cataract, other severe ocular abnormalities not usually seen in subjects with the condition under study, or significant retinal or choroidal vascular abnormalities seen on fluorescein angiogram deemed related to study drug by the investigator.

Up to approximately 12 weeks
Number of Participants Who Experienced an Adverse Event (AE)
Tijdsspanne: Up to approximately 12 weeks

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to approximately 12 weeks
Number of Participants Who Experienced a Serious Adverse Event (SAE)
Tijdsspanne: Up to approximately 24 weeks

An SAE is defined as any adverse experience occurring at any dose that results in any of the following outcomes: Results in death; Is life threatening (immediate risk of death); results in persistent or significant disability/incapacity; requires participant hospitalization or prolongs participant hospitalization; or results in a congenital anomaly/birth defect in a neonate/infant

Up to approximately 24 weeks
Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory Assessments
Tijdsspanne: Baseline and Week 12

Clinical laboratory tests, including overnight fasting serum chemistry, lipid panel, hematology, and coagulation panel were collected at baseline and at week 12 study visit. Any laboratory test result considered by the investigator to be clinically significant was considered to be an AE. Clinically significant abnormal values were followed up until repeat test results return to normal, stabilize, or are no longer clinically significant.

Baseline and Week 12
Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME Participants
Tijdsspanne: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

Baseline and Week 12
Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD Participants
Tijdsspanne: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

Baseline and Week 12

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Participants With ETDRS BCVA Response- Treatment-Naive DME Participants
Tijdsspanne: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Number of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD Participants
Tijdsspanne: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Mean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME Participants
Tijdsspanne: Baseline and 12 weeks

SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

Baseline and 12 weeks
Mean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD Participants
Tijdsspanne: Baseline and 12 weeks

SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

Baseline and 12 weeks
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME Participants
Tijdsspanne: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD Participants
Tijdsspanne: Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME Participants
Tijdsspanne: Baseline and Week 12

Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

Baseline and Week 12
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD Participants
Tijdsspanne: Baseline and Week 12

Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

Baseline and Week 12

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

12 juni 2023

Primaire voltooiing (Werkelijk)

26 augustus 2024

Studie voltooiing (Werkelijk)

26 augustus 2024

Studieregistratiedata

Eerst ingediend

14 juni 2023

Eerst ingediend dat voldeed aan de QC-criteria

14 juni 2023

Eerst geplaatst (Werkelijk)

26 juni 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

9 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren